Last 45 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -31.59 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 35.51 | 26.72 | 24.59 | 31.26 | 31.67 | 20.74 | 25.53 | 20.61 | 24.11 | 21.54 | 25.09 | 28.08 | 14.74 | 12.20 | 22.05 | 46.63 | 73.49 | 5.77 | 96.76 | 69.03 | 159.59 |
| — | +28.8% | -3.7% | +51.7% | +31.3% | -3.7% | +1.8% | -26.6% | +63.6% | +76.6% | +13.8% | -39.8% | -79.9% | +111.5% | -77.2% | -32.5% | -53.9% | -99.4% | -98.7% | — | — | |
| P/B Ratio | 23.64 | 35.05 | 24.88 | 26.51 | 21.98 | 30.13 | 20.48 | 20.96 | 21.00 | 13.96 | 42.32 | 16.03 | 6.72 | 5.14 | 4.60 | 6.20 | 4.48 | 1.07 | 2.46 | 1.77 | 2.04 |
| — | +16.3% | +21.5% | +26.5% | +4.6% | +115.8% | -51.6% | +30.7% | +212.6% | +171.3% | +819.3% | +158.5% | +50.0% | +381.2% | +87.2% | +251.4% | +119.9% | -61.8% | -9.2% | -77.6% | -58.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.7% | 87.5% | 88.1% | 91.6% | 89.3% | 88.6% | 88.8% | 90.9% | 88.5% | 89.9% | 89.2% | 86.7% | 89.3% | 88.4% | 87.6% | 88.3% | 88.4% | 95.8% | 84.6% | 87.0% | 78.4% |
| — | -1.2% | -0.8% | +0.7% | +0.9% | -1.4% | -0.4% | +4.9% | -0.9% | +1.7% | +1.8% | -1.9% | +1.0% | -7.8% | +3.5% | +1.5% | +12.7% | +91.7% | -4.4% | — | — | |
| Operating Margin | -101.2% | -68.1% | -87.1% | -82.2% | -102.6% | -93.4% | -143.7% | -98.6% | -132.0% | -139.2% | -538.7% | -170.3% | -195.3% | -242.5% | -458.0% | -479.0% | -916.6% | -497.4% | -3517.4% | -2806.2% | -4303.5% |
| — | +27.0% | +39.4% | +16.7% | +22.2% | +32.9% | +73.3% | +42.1% | +32.4% | +42.6% | -17.6% | +64.5% | +78.7% | +51.3% | +87.0% | +82.9% | +78.7% | +96.6% | +96.4% | — | — | |
| Net Margin | -103.6% | -69.2% | -92.6% | -83.0% | -103.1% | -96.1% | -151.4% | -103.5% | -131.2% | -110.9% | -544.4% | -171.8% | -196.2% | -243.0% | -455.0% | -483.4% | -953.8% | -496.4% | -3522.3% | -2359.2% | -3415.1% |
| — | +28.0% | +38.8% | +19.8% | +21.4% | +13.3% | +72.2% | +39.8% | +33.1% | +54.3% | -19.7% | +64.5% | +79.4% | +51.0% | +87.1% | +79.5% | +72.1% | +96.2% | -102.8% | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -90.5% | -21.7% | -21.9% | -16.8% | -24.6% | -31.4% | -30.2% | -27.3% | -26.3% | -26.8% | -122.2% | -22.7% | -23.3% | -23.2% | -21.6% | -15.6% | -17.1% | -20.9% | -20.3% | -14.1% | -10.4% |
| — | +31.1% | +27.5% | +38.5% | +6.2% | -17.5% | +75.3% | -20.4% | -13.0% | -15.2% | -466.9% | -45.5% | -35.7% | -11.4% | -6.2% | -10.2% | -64.5% | -116.0% | -227.0% | +26.4% | +34.9% | |
| ROA | -45.1% | -11.2% | -12.1% | -9.6% | -12.0% | -12.3% | -12.7% | -11.5% | -11.7% | -10.1% | -47.8% | -12.1% | -13.3% | -14.2% | -14.3% | -11.0% | -12.2% | -16.0% | -17.2% | -12.5% | -9.4% |
| — | +8.7% | +5.1% | +16.0% | -2.7% | -21.9% | +73.4% | +5.5% | +12.0% | +29.3% | -233.6% | -10.1% | -8.6% | +11.0% | +16.6% | +12.0% | -29.8% | -83.2% | -219.6% | +27.9% | +36.0% | |
| ROIC | -96.3% | -21.8% | -19.7% | -15.1% | -31.6% | -107.4% | -50.2% | -32.8% | -50.2% | -194.8% | -174.6% | -25.2% | -32.6% | -38.8% | -31.5% | -26.7% | -32.2% | -27.7% | -20.4% | -16.6% | -12.8% |
| — | +79.7% | +60.8% | +54.0% | +37.0% | +44.8% | +71.2% | -30.0% | -54.2% | -401.8% | -454.9% | +5.4% | -1.1% | -40.2% | -54.1% | -60.5% | -151.3% | -165.6% | -44.6% | +36.4% | +24.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -46.0% | -35.2% | -38.2% | -47.0% | +36.8% | +42.4% | +222.4% | +261.9% | +159.1% | +115.8% | +0.9% | -2.5% | -23.3% | -20.6% | -18.1% | -10.4% | +43.5% | +31.4% | -51.6% | -48.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.41 | 3.45 | 4.17 | 4.41 | 4.75 | 2.79 | 3.30 | 3.24 | 3.49 | 6.53 | 4.35 | 5.58 | 6.57 | 6.16 | 6.91 | 8.90 | 10.93 | 5.59 | 5.36 | 7.10 | 14.30 |
| — | +23.9% | +26.2% | +36.1% | +36.1% | -57.3% | -24.1% | -42.0% | -46.9% | +6.1% | -37.0% | -37.2% | -40.0% | +10.1% | +28.8% | +25.3% | -23.6% | -74.2% | -78.1% | -29.7% | +8.0% | |
| Quick Ratio | 4.16 | 3.20 | 3.89 | 4.16 | 4.53 | 2.64 | 3.13 | 3.08 | 3.34 | 6.31 | 4.20 | 5.43 | 6.41 | 6.02 | 6.79 | 8.83 | 10.93 | 5.59 | 5.36 | 7.10 | 14.30 |
| — | +21.4% | +24.3% | +35.3% | +35.5% | -58.2% | -25.4% | -43.3% | -47.8% | +4.8% | -38.2% | -38.5% | -41.4% | +7.7% | +26.6% | +24.3% | -23.6% | -74.2% | -78.1% | -29.7% | +8.0% | |
| Interest Coverage | -8.52 | -9.76 | -11.02 | -9.30 | -10.13 | -6.96 | -8.14 | -6.96 | -7.39 | -5.90 | -28.67 | -8.11 | -12.91 | -13.14 | -16.05 | -13.11 | -18.06 | -977.28 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 45 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RYTM stock.
Rhythm Pharmaceuticals, Inc.'s current P/E is -31.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Rhythm Pharmaceuticals, Inc.'s current operating margin is -101.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Rhythm Pharmaceuticals, Inc.'s business trajectory between earnings reports.